5 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026

2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Greenlight Capital’s Stake: $95 Million 

Increase in Share Price Over Past Six Months: 58%

Institutional sentiment towards Teva Pharmaceutical Industries Limited (NYSE:TEVA) has shifted significantly following Q4 2025 earnings, which many funds used as a signal to accumulate shares. The firm reported an Adjusted EPS of $0.96, crushing the consensus estimate of $0.65. Revenue grew 11.4% year-over-year to $4.71 billion, driven by a massive surge in its innovative portfolio. For the first time, three key innovative brands collectively delivered over $1 billion in a single quarter. In March, Teva received FDA approval for PONLIMSI, a denosumab biosimilar, and filed for a biosimilar to Xolair. Hedge funds track these as high-margin catalysts that will drive revenue through 2027.

Despite Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock surging over 105% in the past year, many top-tier funds believe it remains fundamentally undervalued relative to its new growth profile. In April, major brokerages raised their price targets significantly. Goldman Sachs lifted the target to $45, Bank of America to $42, and Piper Sandler to $41. Filings for the fourth quarter of 2025 show that Greenlight Capital owns just over 3 million shares in the pharma firm, down close to 20% compared to filings for the third quarter of 2025. Teva develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

1281292 - 11759070 - 1